Wednesday, June 10, 2026

Patent intelligence · WO

WO 2019224246

MÉTHODES FONDÉES SUR DES BIOMARQUEURS DESTINÉES AU TRAITEMENT D'UNE MALADIE ATOPIQUE PAR IMMUNOTHÉRAPIE

granted A61K/3935A61P/3708
Status granted
Years to expiry 13
Applicant portfolio 25
Patent details — WO 2019224246
Jurisdiction
WO
Status
granted
Grant date
Nov 28, 2019
Expiration
Nov 23, 2039
Applicant
ALK ABELLO AS [DK]
CPC classes
A61K/3935, A61P/3708
View on Google Patents ↗

Quick answer

WO 2019224246 (MÉTHODES FONDÉES SUR DES BIOMARQUEURS DESTINÉES AU TRAITEMENT D'UNE MALADIE ATOPIQUE PAR IMMUNOTHÉRAPIE) is held by ALK ABELLO AS [DK]. Status: granted. Granted Nov 28, 2019. Expires Nov 23, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ALK ABELLO AS [DK]
Grant date
Expiration
Claims
CPC classes
A61K/3935, A61P/3708

More from ALK ABELLO AS [DK]

Related pharmaceutical patents in our USPTO index.

  1. WO 2024200854

    ANTICORPS DE LIAISON AUX ALLERGÈNES APPROPRIÉS POUR TRAITER DES ALLERGIES AU POLLEN D'ARBRE

    ALK ABELLO AS [DK] · Expires Sep 28, 2044

    granted
  2. EP 4302751

    ORALE DÜNNFILME MIT GERINGER WASSERAKTIVITÄT

    LTS LOHMANN THERAPIE SYSTEME AG [DE] · Expires Jan 5, 2044

    granted
  3. EP 4302750

    ORALE DÜNNFILME ENTHALTEND ADRENALIN

    LTS LOHMANN THERAPIE SYSTEME AG [DE] · Expires Jan 5, 2044

    granted
  4. CA 3259886

    DISPOSITIFS DE DÉPLACEMENT D'IGE-FCERI

    UNIV AARHUS [DK] · Expires Dec 30, 2043

    granted
  5. WO 2023232958

    INHIBITEURS DE LA KINASE DE BRUTON POUR LE TRAITEMENT D'UNE RÉACTION ALLERGIQUE SOUDAINE

    ALK ABELLO AS [DK] · Expires Dec 2, 2043

    granted
  6. CA 3255134

    COMPOSITION D'ALLERGÈNE D'ARACHIDE

    ALK ABELLO AS [DK] · Expires Oct 14, 2043

    granted
  7. HK 1249412

    PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF

    ALK ABELLO AS · Expires Oct 28, 2038

    granted

Frequently asked questions

What is US patent 2019224246?

WO 2019224246 (MÉTHODES FONDÉES SUR DES BIOMARQUEURS DESTINÉES AU TRAITEMENT D'UNE MALADIE ATOPIQUE PAR IMMUNOTHÉRAPIE) is held by ALK ABELLO AS [DK]. Status: granted. Granted Nov 28, 2019. Expires Nov 23, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2019224246?

ALK ABELLO AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does WO 2019224246 expire?

Our index shows an expiration date of Nov 23, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.